Early Access — free while we kick the tires
EdgarHawk

Carter Denise P.

Chief Operating Officer

Director Officer
2 filings analyzed · 1 company · Latest 2024-12-27

Companies

Company Buys Sells Direction
Quoin Pharmaceuticals, Ltd. QNRX 5 0 Net buying

Activity

December 2024
high
Buy
555,556 shares
$250,000
Significance 8/10

COO Carter buys 555.6K shares of QNRX at $0.45, increasing stake by +1179.7%, amid cluster activity and 100% prior win rate.

Carter Denise P. (COO) purchased 555,556 shares at $0.45, escalating her holdings from 47,092 to 602,648 shares—a +1179.7% increase in position size. This transaction occurred within a 14-day cluster window during which 3 other insiders also bought, suggesting aligned confidence among leadership. Notably, Carter's prior 4 trades at QNRX produced an average 90-day return of +3500.9%, with 100% of those trades rising over 90 days—a pattern of consistently well-timed entry points. However, context is critical: the company reported a negative net income of $-2,349,885.00 over its most recent fiscal year, and the stock is currently $19.25, down 89.3% from its 52-week high of $180.14, raising material questions about fundamentals that transcend the favorable historical return metrics.

September 2024
high
Buy
37,735 shares
$28,737
Significance 7/10

COO Carter bought 37,735 shares (37.7K) across 4 transactions for $28,737.13, raising stake to 47,092 shares at blended avg $0.76 while stock down 87.0% from 52-week high

Carter Denise P., Chief Operating Officer, executed 4 separate purchase transactions totaling 37,735 shares for $28,737.13 at an average price of $0.76, expanding holdings by 403.3% from 9,357 to 47,092 shares. The purchases occurred on 2024-09-03 and 2024-09-04 at prices ranging from $0.63 to $0.80. This substantial accumulation is notable given the stock's sharp decline of 87.0% from its 52-week high of $215.60 to current price of $27.91, alongside company unprofitability (net income of $-2.0M). The magnitude of the COO's position increase, particularly at these depressed price levels shortly after a steep drawdown, warrants tracking of whether the executive action reflects conviction about recovery prospects or structural changes within the organization.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access